We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Plant Health Care Plc | LSE:PHC | London | Ordinary Share | GB00B01JC540 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.33 | -8.68% | 3.47 | 3.30 | 3.64 | 3.70 | 3.64 | 3.70 | 110,904 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pesticides, Agric Chems, Nec | 11.77M | -9.48M | -0.0278 | -1.31 | 12.43M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/8/2016 11:45 | hxxp://www.plantheal lots of sound information | dadedidodu | |
10/8/2016 11:44 | ‘PREtec’ platform Plant Health Care is the world leader in Plant Response Elicitor technology, a class of bio-rational agricultural technology known as PREtec. pretec-logo PREtec elicitors selectively activate the innate growth and defense mechanisms of crop plants, leading to higher yields and better protection against pests and pathogens. The Group’s new technology segment is focused on the invention and early development of PREtec signal peptides and the elucidation of their mode of action. Plant Health Care has historic capabilities in this field going back to the discovery and development of Harpins, which are pathogen-derived effector molecules. | dadedidodu | |
10/8/2016 11:44 | ‘PREtec’ platform Plant Health Care is the world leader in Plant Response Elicitor technology, a class of bio-rational agricultural technology known as PREtec. pretec-logo PREtec elicitors selectively activate the innate growth and defense mechanisms of crop plants, leading to higher yields and better protection against pests and pathogens. The Group’s new technology segment is focused on the invention and early development of PREtec signal peptides and the elucidation of their mode of action. Plant Health Care has historic capabilities in this field going back to the discovery and development of Harpins, which are pathogen-derived effector molecules. | dadedidodu | |
10/8/2016 11:41 | top of the movers board now sky ship This could be six bagger | abarclay | |
10/8/2016 11:38 | 24p!!! - Be very careful newcomers - note the massively dilutive placing going through at a mere 10p! | skyship | |
10/8/2016 11:38 | lots of interest here | abarclay | |
10/8/2016 11:30 | only 5,000 shares now avail at 25p on board | abarclay | |
10/8/2016 11:28 | And she's away to the races | abarclay | |
10/8/2016 11:26 | Avoid like the plague Unmitigated disaster | abarclay | |
10/8/2016 11:25 | MASSIVE BOWL ON CHART TO 120p | abarclay | |
28/7/2016 12:22 | Chart and above comments appear (imo) to be saying PHC is on the way out - Not sure if any value left in the IP - | pugugly | |
19/6/2016 11:31 | Yes - phc is a lemon! | targatarga | |
19/6/2016 08:38 | Any news on the big drop on Friday? | leonmoon | |
09/4/2016 11:56 | Thanks for that Thomas. Held these for a good while now and they are pretty volatile. Have you got the full broker report that you could post on here? Have considered topping up but £38m market cap seems high enough for a company that has never turned a profit and whose losses are likely to continue in the next couple years. Also, they are going to require further funding later this year. Also some of the patent protection starts to expire in 2017 (although presumably not the 3G products). | callumross | |
08/4/2016 14:30 | Read Liberum's note on Plant Health Care (PHC), out this morning, by visiting www.research-tree.co “FY15 sales +9% (+15% in l.c.) with gross margins jumping to 62% from 51% last year with better product mix. A doubling R&D led to higher opex driving FY net loss to $8m vs. $6m in FY14. Net cash ended FY15 at $8.4m vs. $16.6m last year. Looking ahead we are not changing estimates materially. We expect further sales growth in existing products and R&D ramp up. PHC is excited by R&D progress and expects to introduce a 2nd peptide family for evaluation this year with trials for the 1st peptide family (Innatus 3G) going well. Innatus 3G license auctions are now expected in 2017/18. Licenses for its other peptide technologies are targeted earlier than this. We believe the recent share price fall is vastly overdone...” | thomasthetank1 | |
17/9/2015 12:53 | LONDON (Alliance News) - Liberum said the narrowed pretax profit loss reported by Plant Health Care for the first half of 2015 was in line with the broker's expectations, who retained a Hold stance on the stock. For the half year to end-June, the company reported a pretax loss of USD3.0 million, narrowed from a pretax loss of USD3.7 million, as a slight decline in revenue to USD3.2 million from USD3.3 million was offset by lower sales and marketing and administrative costs. Liberum noted that Plant Health Care, which provides biological products for the agriculture markets, "remains excited" about the prospects for the agreement the group signed with an agriculture company related to its Innatus 3G peptide platform. Innatus technology enables the design, screening and production of a large pipeline of peptides with diverse bio-stimulant properties. The peptides can provide improved yields, pest and disease resistance, and protection against abiotic stress in a wide range of crops, Plant Health Care said back in June, when the agreement was announced, with no financial details. The broker said it believes that Plant's bio-stimulant technology could be "transformational" and generate substantial revenues. However, Liberum warned that the commercial business remains loss making and the first Innatus revenues are not expected until 2017. Liberum retained its 120 pence price target. Shares in Plant Health Care were untraded Monday at 98p, having dropped by 17% year to date. By Daniel Ruiz; danielruiz@alliancen | callumross | |
08/4/2015 08:54 | Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to the global agriculture markets, is pleased to announce that it has signed an agreement with a major industry player in the agricultural space regarding the evaluation of its Innatus(TM) 3G peptide platform. No name given ? Licensing out their IP to large scale users, with royalties on sales to follow, could be a game changer. A bit like a small biotech licensing an early stage drug development to a big pharmaceutical company. | mdrans1 | |
17/2/2015 21:56 | Richard Griffiths now upto 20% | oilbuy | |
06/11/2014 19:07 | Yes indeed coincall. | blueball | |
06/11/2014 18:37 | What price now blueball? | coincall | |
03/11/2014 17:09 | 95p today looking good for 100p. | blueball | |
07/6/2014 17:04 | Richard Griffiths just bought some more shares now he owns 17%. He can see this share turning cash flow positive soon. | johnsmith321 | |
26/3/2014 09:30 | Glad I got out of this one now at 60p. | callumross | |
24/3/2014 07:52 | A great pile of nothing - Announcement is great for the first paragraphs. THEN get onto the accounts for a LOSS of 6,883,000. OK Revenue improving but (imo) no way this will become cash flow positive in teh foreseeable future. Other views ?? | pugugly |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions